<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353781</url>
  </required_header>
  <id_info>
    <org_study_id>D3610C00004</org_study_id>
    <nct_id>NCT01353781</nct_id>
  </id_info>
  <brief_title>Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing
      schedules in Japanese patients with advanced solid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety and tolerability of AZD5363 to define a Recommended Dose (RD) when given orally</measure>
    <time_frame>All AEs will be collected throughout the study, from informed consent until 30 days after the end of study treatment. The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive</time_frame>
    <description>To investigate the safety and tolerability of AZD5363 to define a Recommended Dose (RD) when given orally, either as a continuous or an intermittent schedule, for further clinical evaluation when given to Japanese patients with advanced solid malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To define the maximum tolerated dose (MTD) if possible or biological effective dose in Japanese patients with advanced solid malignancies.</measure>
    <time_frame>once 2 or more participants experience a DLT a dose level during the study period (within approx 20 months)</time_frame>
    <description>To define the maximum tolerated dose (MTD) if possible or biological effective dose in Japanese patients with advanced solid malignancies. A dose will be considered non-tolerated and dose escalation will cease if 2 or more of up to 6 evaluable patients experience a DLT at a dose level. Six evaluable patients are required to determine the MTD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics parameters Cmin</measure>
    <time_frame>PK measurements on Cycle 0 Day 1/2/3 and Cycle 1 Day 1/8/15.</time_frame>
    <description>To characterise the pharmacokinetics parameters Cmin of AZD5363 following a single administration and after multiple dosing when given orally to Japanese patients with advanced solid malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain a preliminary assessment of the anti-tumour activity of AZD5363 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in Japanese patients with advanced solid malignancies</measure>
    <time_frame>Assessed every 3 weeks for initial 2 cycles and every 6 weeks for later cycles for all subjects after start of study treatment until discontinuation of study treatment or withdrawal of consent.</time_frame>
    <description>To obtain a preliminary assessment of the anti-tumour activity of AZD5363 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in Japanese patients with advanced solid malignancies.
The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics parameters(Cmax)</measure>
    <time_frame>PK measurements on Cycle 0 Day 1/2/3 and Cycle 1 Day 1/8/15.</time_frame>
    <description>To characterise the pharmacokinetics parameters Cmax of AZD5363 following a single administration and after multiple dosing when given orally to Japanese patients with advanced solid malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics parameters tmax</measure>
    <time_frame>PK measurements on Cycle 0 Day 1/2/3 and Cycle 1 Day 1/8/15.</time_frame>
    <description>To characterise the pharmacokinetics parameters tmax of AZD5363 following a single administration and after multiple dosing when given orally to Japanese patients with advanced solid malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics parameters AUC</measure>
    <time_frame>PK measurements on Cycle 0 Day 1/2/3 and Cycle 1 Day 1/8/15.</time_frame>
    <description>To characterise the pharmacokinetics parameters AUC factor of AZD5363 following a single administration and after multiple dosing when given orally to Japanese patients with advanced solid malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics parameters CL/F</measure>
    <time_frame>PK measurements on Cycle 0 Day 1/2/3 and Cycle 1 Day 1/8/15.</time_frame>
    <description>To characterise the pharmacokinetics parameters CL/F factor of AZD5363 following a single administration and after multiple dosing when given orally to Japanese patients with advanced solid malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterise the pharmacokinetics parameters Vz/F</measure>
    <time_frame>PK measurements on Cycle 0 Day 1/2/3 and Cycle 1 Day 1/8/15.</time_frame>
    <description>To characterise the pharmacokinetics parameters Vz/F of AZD5363 following a single administration and after multiple dosing when given orally to Japanese patients with advanced solid malignancies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Advanced Solid Malignancy</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>AZD5363</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5363</intervention_name>
    <description>Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.</description>
    <arm_group_label>AZD5363</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 20 years

          -  Histological or cytological confirmation of a solid malignant tumour, excluding
             lymphoma, that is refractory to standard therapies or for which no standard therapies
             exist

          -  At least one lesion (measurable and/or non-measurable) that can be accurately assessed
             according to RECIST

          -  World Health Organisation (WHO) performance status 0-1 with no deterioration over the
             previous 2 weeks and minimum life expectancy of 12 weeks

          -  Patients should be willing to remain in hospital until the completion of the first
             cycle including cycle 0, cycle 1, and cycle 2 Day1 (as cycle 1 Day 21)

        Exclusion Criteria:

          -  Clinically significant abnormalities of glucose metabolism as defined by any of the
             following:

          -  Diagnosis of diabetes mellitus type I or II (irrespective of management)

          -  Baseline fasting glucose value of â‰¥7 mmol/l (126mg/dL)

          -  Glycosylated haemoglobin (HbA1C) &gt;6.5%

          -  Spinal cord compression or brain metastases unless asymptomatic, treated and stable
             and not requiring steroids for at least 4 weeks prior to start of study treatment

          -  Inadequate bone marrow reserve or organ function

          -  Any evidence of severe or uncontrolled systemic diseases, including active bleeding
             diatheses, or active infection

          -  With the exception of alopecia, any unresolved toxicities from prior therapy greater
             than CTCAE grade 1 at the time of starting study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Stockman, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1364&amp;filename=d3610c00004_protocol_protocol%20amendments_Redacted_JPOL%20MP%2011APR_Redacted....pdf</url>
    <description>d3610c00004_protocol_protocol amendments_Redacted_JPOL MP 11APR_Redacted....pdf</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>AKT</keyword>
  <keyword>Ascending</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

